{"product_id":"retatrutide-glp-3r","title":"Reta GLP-3R","description":"\u003cp\u003eReta is an investigational tri-agonist peptide studied for its interaction with three key receptor systems: GLP-1, GIP, and GCGR (glucagon). In research settings, it is examined for its ability to engage these pathways simultaneously, allowing scientists to explore multi-receptor activity within metabolic experimental models.\u003c\/p\u003e\n\u003cp\u003eReta activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. GLP-1 receptor activation promotes insulin secretion, reduces appetite, and slows gastric emptying. GIP receptor activation enhances the incretin effect on beta cells and may influence adipose tissue metabolism. Glucagon receptor activation increases hepatic glucose output and energy expenditure. The combination of all three agonist activities in a single molecule distinguishes GLP-3 R from dual-agonist compounds.\u003c\/p\u003e\n\u003cdiv class=\"elementor-element elementor-element-70108bd elementor-widget elementor-widget-heading\" data-id=\"70108bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003ePen Dosage Chart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-a2c1f5a color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"a2c1f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\" style=\"width: 100%;\"\u003e\n\u003ccolgroup\u003e \u003ccol width=\"50%\" style=\"width: 21.033868%;\"\u003e \u003ccol width=\"50%\" style=\"width: 78.787879%;\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eReta GLP-3R 12mg QuickPen Pro\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003e3.0 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emg\/mL\u003c\/td\u003e\n\u003ctd\u003e4 mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClick-to-Dose\u003c\/td\u003e\n\u003ctd\u003e1 click = 0.04 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample(s)\u003c\/td\u003e\n\u003ctd\u003e30 clicks(10 of Pen Scale) = 1.2 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"425\" data-end=\"839\"\u003e \u003c\/p\u003e\n\u003cdiv data-widget_type=\"heading.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"461454e\" class=\"elementor-element elementor-element-461454e elementor-widget elementor-widget-heading\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eMechanism of Action\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"89ab6a4\" class=\"elementor-element elementor-element-89ab6a4 color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003cp\u003eAs a unimolecular agonist, Rеtаtrutіdе binds to GLP-1R, GIPR, and GCGR with high affinity, leading to cAMP-mediated signaling cascades that enhance pancreatic beta-cell insulin release, suppress glucagon in hyperglycemia, and increase hepatic fatty acid oxidation. In animal models, this results in upregulated thermogenesis via UCP1 in brown adipose tissue and reduced lipogenesis. In vitro studies confirm synergistic receptor crosstalk, amplifying AMPK activation for improved mitochondrial function and reduced inflammation markers like CRP.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"menu-anchor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"bf2e85c\" class=\"elementor-element elementor-element-bf2e85c elementor-widget elementor-widget-menu-anchor\"\u003e\n\u003cdiv id=\"3\" class=\"elementor-menu-anchor\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"heading.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"3839bb6\" class=\"elementor-element elementor-element-3839bb6 elementor-widget elementor-widget-heading\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eBenefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"a88a59d\" class=\"elementor-element elementor-element-a88a59d color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eTriple Agonist Mechanism for Comprehensive Metabolic Regulation\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе is a potent \u003cb\u003eGLP-1, GIP, and glucagon receptor agonist\u003c\/b\u003e, studied for its multi-pathway activation of energy metabolism. By engaging all three receptors, it enhances insulin secretion, suppresses appetite, and promotes lipid oxidation simultaneously. This triple agonist design provides broader metabolic modulation than single or dual incretin analogs, making it a leading subject in next-generation obesity and diabetes research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eExceptional Weight Reduction Outcomes\u003c\/b\u003e:\u003cbr\u003eClinical and preclinical data show that Rеtаtrutіdе can produce \u003cb\u003eup to 24% body weight reduction\u003c\/b\u003e over extended treatment periods. This outcome surpasses previous GLP-1 or GLP-1\/GIP agonists due to enhanced thermogenesis and fat oxidation mechanisms. Research indicates a sustained and progressive decline in both subcutaneous and visceral fat mass, positioning Rеtаtrutіdе as a new benchmark in metabolic optimization studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMarked Reduction in Visceral and Hepatic Fat\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе has been observed to dramatically \u003cb\u003ereduce liver fat content\u003c\/b\u003e (over 80% in clinical data) and visceral adiposity in both obese and type 2 diabetic subjects. This effect stems from its ability to activate glucagon receptor-mediated lipid metabolism and enhance mitochondrial β-oxidation, promoting improved liver function and systemic metabolic balance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImprovement in Glucose Control and Insulin Sensitivity\u003c\/b\u003e:\u003cbr\u003eThrough simultaneous activation of incretin pathways, Rеtаtrutіdе enhances \u003cb\u003einsulin secretion\u003c\/b\u003e, suppresses glucagon, and improves peripheral glucose uptake. This coordinated metabolic effect results in significant HbA1c reduction and stabilization of fasting glucose levels in research subjects. These findings highlight its potential as one of the most effective glucose-lowering peptides under investigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Lipid Profile and Cardiovascular Markers\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе administration has been associated with improved \u003cb\u003elipid metabolism\u003c\/b\u003e, including reductions in total cholesterol, LDL, and triglycerides. Studies also report lower systolic blood pressure and inflammatory markers such as CRP, suggesting favorable cardiometabolic outcomes in long-term metabolic studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStimulation of Energy Expenditure and Thermogenesis\u003c\/b\u003e:\u003cbr\u003eIn animal models, Rеtаtrutіdе increases \u003cb\u003ethermogenic activity\u003c\/b\u003e in brown adipose tissue via glucagon receptor signaling, leading to higher resting energy expenditure. Enhanced mitochondrial respiration and fatty acid oxidation contribute to continuous fat loss even under moderate caloric intake, establishing its potential as a metabolic rate enhancer in research applications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eReduction of Systemic Inflammation\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе has been observed to \u003cb\u003ereduce inflammatory cytokines\u003c\/b\u003e such as TNF-α and IL-6, while improving endothelial function and vascular elasticity. These anti-inflammatory and vasoprotective effects complement its metabolic actions, promoting improved cardiovascular resilience in experimental models of metabolic disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePreservation of Lean Body Mass\u003c\/b\u003e:\u003cbr\u003eResearch findings suggest that despite substantial fat loss, Rеtаtrutіdе supports the \u003cb\u003emaintenance of lean muscle tissue\u003c\/b\u003e. This balance between adipose reduction and muscle preservation reflects its unique energy-partitioning effect, making it valuable for studies exploring body recomposition and athletic performance enhancement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eLiver Function and NAFLD Improvement\u003c\/b\u003e:\u003cbr\u003ePreclinical and early clinical studies show significant improvements in \u003cb\u003enon-alcoholic fatty liver disease (NAFLD)\u003c\/b\u003e parameters, including reduced hepatic inflammation and fibrosis. Rеtаtrutіdе’s triple-agonist activation enhances AMPK signaling, reducing lipid accumulation and promoting hepatic regeneration in metabolic liver research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSynergistic Effects with GLP-1 and Mitochondrial Peptides\u003c\/b\u003e:\u003cbr\u003eExperimental protocols combining Rеtаtrutіdе with \u003cstrong\u003eS\u003c\/strong\u003e\u003cstrong\u003eеmаglutіdе\u003c\/strong\u003e\u003cb\u003e, MOTS-c, or SS-31\u003c\/b\u003e are being explored to enhance mitochondrial bioenergetics, lipid metabolism, and overall metabolic performance. These stacked combinations aim to maximize fat oxidation, reduce inflammation, and sustain high energy efficiency in long-term research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eLong-Term Metabolic Adaptation and Weight Maintenance\u003c\/b\u003e:\u003cbr\u003eFollow-up studies indicate that subjects maintained over \u003cb\u003e80% of their weight loss\u003c\/b\u003e after extended observation periods, even after discontinuation. This sustained adaptation reflects durable improvements in metabolic set-point, appetite control, and mitochondrial efficiency, marking Rеtаtrutіdе as a highly promising agent for advanced metabolic research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStandard Research Protocol\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDose: 2 – 4 mg weekly, titrate to 12 mg\u003c\/li\u003e\n\u003cli\u003eDuration: 20 – 48 weeks\u003c\/li\u003e\n\u003cli\u003eFrequency: 1× weekly\u003c\/li\u003e\n\u003cli\u003eCycle Interval: 20 – 48 weeks on, 4 – 8 weeks off, then reassess\u003c\/li\u003e\n\u003cli\u003eGoal \/ Description: Gradual weight reduction, improved glycemic markers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eGlucose-Focus Protocol\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDose: 0.25 – 1.0 mg weekly\u003c\/li\u003e\n\u003cli\u003eDuration: 8 – 10 weeks\u003c\/li\u003e\n\u003cli\u003eFrequency: 1× weekly\u003c\/li\u003e\n\u003cli\u003eCycle Interval: 8 – 10 weeks on, 4 weeks off\u003c\/li\u003e\n\u003cli\u003eGoal \/ Description: Improved fasting\/postprandial control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"12mg","offer_id":57222187614585,"sku":null,"price":209.0,"currency_code":"EUR","in_stock":true},{"title":"20mg","offer_id":57222187647353,"sku":null,"price":280.0,"currency_code":"EUR","in_stock":true},{"title":"30mg","offer_id":57222187680121,"sku":null,"price":336.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/reta-glp-3r-7025321.png?v=1778161511","url":"https:\/\/www.quickpen.pro\/products\/retatrutide-glp-3r","provider":"Quickpen Pro Peptides","version":"1.0","type":"link"}